Sugi Predict

Sugi Predict / Compounds / SCHEMBL2180252

SCHEMBL2180252

SCHEMBL2180252

CC(C)(C)OC(=O)N[C@@H]1CCNC[C@H]1O

nearest known ligand 0.43

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 1/20 0.43
▸ GAA P10253 2/20 0.39
▸ EPHX1 P07099 1/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ CTSK P43235 2/20 0.38
▸ KDM1A O60341 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ SSTR4 P31391 2/20 0.37
▸ SSTR1 P30872 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2490021 1.00 BTK (0.43) BTKGAAEPHX1EPHX2NFKB1
SCHEMBL13767380 1.00 BTK (0.43) BTKGAAEPHX1EPHX2NFKB1
SCHEMBL30111928 1.00 BTK (0.43) BTKGAAEPHX1EPHX2NFKB1
SCHEMBL2490017 1.00 BTK (0.43) BTKGAAEPHX1EPHX2NFKB1
SCHEMBL2180249 1.00 BTK (0.43) BTKGAAEPHX1EPHX2NFKB1
SCHEMBL2180246 1.00 BTK (0.43) BTKGAAEPHX1EPHX2NFKB1
Carbamic Acid SCHEMBL4770752 0.94 BTK (0.43) BTKGAAEPHX1EPHX2NFKB1
SCHEMBL4765504 0.92 BTK (0.42) BTKGAAEPHX1EPHX2NFKB1
SCHEMBL14040699 0.92 BTK (0.42) BTKGAAEPHX1EPHX2NFKB1
SCHEMBL14131624 0.92 BTK (0.42) BTKGAAEPHX1EPHX2NFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106389-A1 NMT INHIBITOR AND USE THEREOF 주식회사 이노보테라퓨틱스 2026-05-21 — — WO disclosed
US-20260132122-A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS INCYTE CORP (US) 2026-05-14 — — US disclosed
US-20260125391-A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS INCYTE CORP (US) 2026-05-07 — — US disclosed
US-12617782-B2 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2026-05-05 — — US disclosed
US-20260070914-A1 SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS INCYTE CORP (US) 2026-03-12 — — US disclosed
US-20260070915-A1 SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS INCYTE CORP (US) 2026-03-12 — — US disclosed
US-12503452-B2 Antimicrobial compounds and methods CURZA GLOBAL, LLC (US) 2025-12-23 — — US disclosed
US-20250066357-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2025-02-27 — — US disclosed
US-12187721-B2 Protein tyrosine phosphatase inhibitors ARRAY BIOPHARMA INC. (US) 2025-01-07 — — US disclosed
WO-2024253416-A1 PYRIMIDINE/PYRIDINE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME YUHAN CORPORATION (KR) 2024-12-12 — — WO disclosed
EP-1699797-B1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2009-09-23 — — EP disclosed
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-02-19 — — US disclosed
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-02-19 — — US disclosed
US-7297695-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-20 — — US disclosed
US-7297695-B2 Pyrrolotriazine compounds as kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2007-11-20 — — US disclosed
WO-2007016610-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2007-02-08 — — WO disclosed
EP-1578743-A4 ANTIBACTERIAL AGENTS GLAXO GROUP LTD (GB) 2006-11-29 — — EP disclosed
US-20060041123-A1 Antibacterial agents GLAXO GROUP LIMITED (GB) 2006-02-23 — — US disclosed
EP-1578743-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2005-09-28 — — EP disclosed
WO-2004058144-A2 ANTIBACTERIAL AGENTS GLAXO GROUP LIMITED (GB) 2004-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260070915-A1 SUBSTITUTED 7H-PYRROLO[2,3-D]PYRIMIDIN-2-AMINES AS SELECTIVE CDK2/4 INHIBITORS CDK4, CDK2, CCNC BTK 486/4885GAA 3867/4885EPHX1 3519/4885
US-20250066357-A1 PROTEIN TYROSINE PHOSPHATASE INHIBITORS PPM1A, PPM1F, PPP5C BTK 93/4885GAA 885/4885EPHX1 2524/4885
US-12187721-B2 Protein tyrosine phosphatase inhibitors PPM1A, PTP4A1, PPP5C BTK 94/4885GAA 820/4885EPHX1 2337/4885
US-20260070914-A1 SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS CCNA1, CCNO, CDK1 BTK 1433/4885GAA 4809/4885EPHX1 1714/4885
US-20260132122-A1 6-6-FUSED BICYCLIC HETEROARYL AMINES AS CDK4 INHIBITORS CCNA1, CDK4, CCNO BTK 637/4885GAA 4570/4885EPHX1 2031/4885
US-12617782-B2 Pyridazinones as PARP7 inhibitors PARP3, PARP2, PARP1 BTK 2174/4885GAA 4352/4885EPHX1 2674/4885
US-20060041123-A1 Antibacterial agents NQO2, NRDC, IFNG BTK 3378/4885GAA 314/4885EPHX1 3422/4885
US-20260125391-A1 PYRIMIDINE INDOLES AS CDK4 INHIBITORS CDK4, CCNA1, CCNO BTK 731/4885GAA 4146/4885EPHX1 3089/4885
US-20090048244-A1 PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS ERBB2, ERBB4, ERBB3 BTK 253/4885GAA 1657/4885EPHX1 3540/4885
US-12503452-B2 Antimicrobial compounds and methods MPO, NISCH, RPN2 BTK 1068/4885GAA 173/4885EPHX1 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.